Bristol-Myers Squibb to create immunotherapy cancer drug research centre in California

Published: 25-Jul-2014
Research & Development Pharmaceutical

Will expand its Redwood City Campus with laboratories to conduct biologics drug discovery


Bristol-Myers Squibb is to create a research hub at Redwood City, California, for discovering cancer drugs in the emerging field of immunotherapy.

The company has signed a 10-year lease to expand its Redwood City campus in BioMed Realty's Woodside Technology Park life science campus by approximately 61,000ft2. The company will add laboratories that will provide additional capacity to conduct biologics drug discovery research in addition to office space.

Bristol-Myers Squibb will occupy two of the three buildings at the campus, totalling 194,100ft2, as the company further strengthens its presence in the San Francisco Bay Area, said BioMed Realty.

  • Companies:
  • Bristol-Myers Squibb
See more

You may also like

Research & Development

Elekta and Bristol Myers Squibb partner on digital solution for patients with melanoma

Read more
Elekta announces a pilot collaboration with Bristol Myers Squibb to develop a digital solution for patients with melanoma.

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  4. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  5. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Elekta and Bristol Myers Squibb partner on digital solution for patients with melanoma

Elekta announces a pilot collaboration with Bristol Myers Squibb to develop a digital solution for patients with melanoma.
Finance

Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb

The biotech company focuses on developing new drugs for fibrotic and other inflammatory diseases
Research & Development

Bristol-Myers Squibb invests in drug development accelerator BioMotiv

The pharmaceutical giant seeks to accelerate scientific discoveries into breakthrough therapies for patients living with severe diseases
Design & Build

Catalent to acquire Bristol-Myers Squibb manufacturing plant in Italy

Facility in Anagni is equipped with oral solid, biologics, and sterile product manufacturing and packaging capabilities
Research & Development

Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies

Biocartis Group has signed a collaboration agreement with Bristol-Myers Squibb to register and use the Idylla MSI test in connection with immuno-oncology therapies
Media

BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants

Following the Bristol-Myers Squibb (BMS) announcement on 3 January 2019 that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, offers her view on this significant merger
Finance

Bristol-Myers Squibb to merge with Celgene in multimillion deal

Transaction will see a combined pharmaceutical company in pole position within the immuno-oncology and the treatment of blood cancers market
Subscribe now